Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 34 of 34 results for copyright

  1. Freedom of Information

    Freedom of Information

  2. Freedom of information publication scheme

    of health, public health and social care. View our guidance Copyright The copyright in the material listed in this...

  3. Terms and conditions

    Terms and conditions for the National Institute for Health and Care Excellence

  4. Chemotherapy dose standardisation: NICE position statement

    ensure that NICE processes, tools and resources are suitably aligned. Copyright © NICE 2018. All rights reserved. Subject to Notice of...

  5. Core standards (Agents)

    Purchasing framework core service requirements

  6. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

  7. Evidence summaries: new medicines – Interim process statement (PMG1)

    Evidence summaries: new medicines – Interim process statement

  8. Interim clinical guideline surveillance process and methods guide 2013 (PMG16)

    Interim clinical guideline surveillance process and methods guide 2013

  9. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  10. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013

  11. Insertion of hydrogel keratoprosthesis (IPG69)

    Evidence-based recommendations on insertion of hydrogel keratoprosthesis. This involves putting an artificial cornea into place in a pocket made in the front part of the eye.

  12. Good practice guidance – Interim process statement (PMG3)

    Good practice guidance – Interim process statement

  13. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    Evidence summaries: unlicensed and off-label medicines – Interim process statement

  14. Intravenous fluid therapy in adults in hospital (CG174)

    This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.

  15. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.

  16. Core standards (non-Agents)

    right to provide or which it has reasonable grounds to believe infringes copyright; or is defamatory, obscene, unlawful or otherwise...

  17. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  18. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  19. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

  20. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  21. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  22. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  23. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  24. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  25. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  26. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  27. Guide to the processes of technology appraisal (PMG19)

    Guide to the processes of technology appraisal

  28. Interim methods guide for developing service guidance 2014 (PMG8)

    Interim methods guide for developing service guidance 2014

  29. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  30. Interventional procedures programme manual (PMG28)

    Interventional procedures programme manual

  31. The NICE public health guidance development process (third edition) (PMG5)

    The NICE public health guidance development process (third edition)

  32. NICE health technology evaluations: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website.

  33. The social care guidance manual (PMG10)

    The social care guidance manual

  34. Methods for the development of NICE public health guidance (third edition) (PMG4)

    Methods for the development of NICE public health guidance (third edition)